Abstract
The role of tumor suppressor protein p53 is undeniable in the suppression of cancer upon oncogenic stress. It induces diverse conditions such as cell-cycle arrest, cell death, and senescence to protect the cell from carcinogenesis. The rate of mutations in p53 gene nearly accounts for 50% of the human cancers. Upon mutations, the conformation gets altered and becomes non-native. Mutant p53 displays long half-life and accumulates in the nucleus and interacts with oncoproteins to promote carcinogenesis and these interactions present a formidable challenge for clinicians in therapy of the disease. Variety of approaches have been developed, through which native-like function of p53 can be restored, such as restoration of the native-like structure of p53, activating the p53 family members, etc. Modern scientific techniques have led to the discovery of a variety of molecules to reactivate mutant p53 and restore its transcriptional activity. These compounds include small molecules, various peptides, and phytochemicals. In this review article, we comprehensively discuss these molecules to reactivate mutant p53 to restore the normal function with a particular focus on molecular mechanisms.
Similar content being viewed by others
References
Menendez D, Inga A, Resnick MA (2009) The expanding universe of p53 targets. Nat Rev Cancer 9(10):724–737
Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, Hainaut P (2011) Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther 18(1):2–11. https://doi.org/10.1038/cgt.2010.63
Muller PAJ, Vousden KH, Norman JC (2011) p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192(2):209–218. https://doi.org/10.1083/jcb.201009059
Brown CJ, Cheok CF, Verma CS, Lane DP Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci 32(1):53–62. https://doi.org/10.1016/j.tips.2010.11.004
Stindt MH, Muller PA, Ludwig RL, Kehrloesser S, Dotsch V, Vousden KH (2015) Functional interplay between MDM2, p63/p73 and mutant p53. Oncogene 34(33):4300–4310. https://doi.org/10.1038/onc.2014.359
Sherman M, Gabai V, O’Callaghan C, Yaglom J (2007) Molecular chaperones regulate p53 and suppress senescence programs. FEBS Lett 581(19):3711–3715. https://doi.org/10.1016/j.febslet.2007.05.036
Muller PAJ, Vousden KH (2013) p53 mutations in cancer. Nat Cell Biol 15(1):2–8
Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253(5015):49–53
Brosh R, Rotter V (2009) When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9(10):701–713. https://doi.org/10.1038/nrc2693
Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rozenfeld N (2013) Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23(5):634–646
Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, Wang Q, Zambetti GP, Schuetz JD (2001) Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276(42):39359–39367
Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119(6):861–872. https://doi.org/10.1016/j.cell.2004.11.006
Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, Van Pelt CS, Lozano G (2008) The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 22(10):1337–1344. https://doi.org/10.1101/gad.1662908
Parrales A, Iwakuma T (2015) Targeting oncogenic mutant p53 for cancer therapy. Front Oncol 5:288. https://doi.org/10.3389/fonc.2015.00288
Martins CP, Brown-Swigart L, Evan GI (2006) Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127(7):1323–1334. https://doi.org/10.1016/j.cell.2006.12.007
Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445(7128):661–665. https://doi.org/10.1038/nature05541
Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445(7128):656–660. https://doi.org/10.1038/nature05529
Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM (2015) Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature 523(7560):352–356. https://doi.org/10.1038/nature14430
Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, Tian B, Lowe SW, Silva JM, Borresen-Dale AL, Levine AJ, Bargonetti J, Prives C (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148(1–2):244–258. https://doi.org/10.1016/j.cell.2011.12.017
Masciarelli S, Fontemaggi G, Di Agostino S, Donzelli S, Carcarino E, Strano S, Blandino G (2014) Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. Oncogene 33(12):1601–1608. https://doi.org/10.1038/onc.2013.106
Weisz L, Oren M, Rotter V (2007) Transcription regulation by mutant p53. Oncogene 26(15):2202–2211. https://doi.org/10.1038/sj.onc.1210294
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70
Selivanova G, Kawasaki T, Ryabchenko L, Wiman KG (1998) Reactivation of mutant p53: a new strategy for cancer therapy. Semin Cancer Biol 8(5):369–378
Zhang W, Guo XY, Hu GY, Liu WB, Shay JW, Deisseroth AB (1994) A temperature-sensitive mutant of human p53. EMBO J 13(11):2535–2544
Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, Nikolova PV, Proctor MR, Rudiger S, Fersht AR (2002) A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA 99(2):937–942. https://doi.org/10.1073/pnas.241629998
Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, Grafstrom RC, Wiman KG (1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 3(6):632–638
Bykov VJN, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J, Selivanova G, Wiman KG (2005) Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 280(34):30384–30391. https://doi.org/10.1074/jbc.M501664200
Liu WL, Midgley C, Stephen C, Saville M, Lane DP (2001) Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein. J Mol Biol 313(4):711–731. https://doi.org/10.1006/jmbi.2001.5082
Nikolova PV, Wong KB, DeDecker B, Henckel J, Fersht AR (2000) Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J 19(3):370–378. https://doi.org/10.1093/emboj/19.3.370
Bykov VJ, Wiman KG (2014) Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett 588(16):2622–2627. https://doi.org/10.1016/j.febslet.2014.04.017
Foster BA, Coffey HA, Morin MJ, Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286(5449):2507–2510
Wang W, Takimoto R, Rastinejad F, El-Deiry WS (2003) Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 23(6):2171–2181
Rao CV, Swamy MV, Patlolla JMR, Kopelovich L (2008) Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator in APCmin/+ mice. Cancer Res 68(18):7670–7675. https://doi.org/10.1158/0008-5472.can-08-1610
Tang X, Zhu Y, Han L, Kim AL, Kopelovich L, Bickers DR, Athar M (2007) CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J Clin Investig 117(12):3753–3764. https://doi.org/10.1172/jci32481
Fiorini C, Menegazzi M, Padroni C, Dando I, Dalla Pozza E, Gregorelli A, Costanzo C, Palmieri M, Donadelli M (2013) Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis. Apoptosis 18(3):337–346. https://doi.org/10.1007/s10495-012-0790-6
Hainaut P, Milner J (1993) Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Can Res 53(19):4469–4473
Zache N, Lambert JMR, Rökaeus N, Shen J, Hainaut P, Bergman J, Wiman KG, Bykov VJN (2008) Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol Oncol 2(1):70–80. https://doi.org/10.1016/j.molonc.2008.02.004
Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8(3):282–288. https://doi.org/10.1038/nm0302-282
Duffy MJ, Synnott NC, McGowan PM, Crown J, O’Connor D, Gallagher WM (2014) p53 as a target for the treatment of cancer. Cancer Treat Rev 40(10):1153–1160. https://doi.org/10.1016/j.ctrv.2014.10.004
Zandi R, Selivanova G, Christensen CL, Gerds TA, Willumsen BM, Poulsen HS (2011) PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin Cancer Res 17(9):2830–2841. https://doi.org/10.1158/1078-0432.ccr-10-3168
Fransson A, Glaessgen D, Alfredsson J, Wiman KG, Bajalica-Lagercrantz S, Mohell N (2016) Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant high-grade serous ovarian cancer. J Ovarian Res 9(1):27. https://doi.org/10.1186/s13048-016-0239-6
Lambert JM, Gorzov P, Veprintsev DB, Söderqvist M, Segerbäck D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJ (2009) PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer cell 15(5):376–388
Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Sales F, van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G (2016) p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib. Eur J Cancer (Oxford England: 1990) 55:98–110. https://doi.org/10.1016/j.ejca.2015.12.002
Rao CV, Patlolla JM, Qian L, Zhang Y, Brewer M, Mohammed A, Desai D, Amin S, Lightfoot S, Kopelovich L (2013) Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice. Neoplasia (New York, NY) 15(9):1018–1027
Bykov VJ, Zhang Q, Zhang M, Ceder S, Abrahmsen L, Wiman KG (2016) Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy. Front Oncol 6:21. https://doi.org/10.3389/fonc.2016.00021
Nahi H, Merup M, Lehmann S, Bengtzen S, Möllgård L, Selivanova G, Wiman K, Paul C (2006) PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br J Haematol 132(2):230–236
Lehmann S, Bykov VJN, Ali D, Andrén O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, Paul C, Wiman KG, Andersson P-O (2012) Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 30(29):3633–3639. https://doi.org/10.1200/jco.2011.40.7783
Saha MN, Chen Y, Chen MH, Chen G, Chang H (2014) Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents. Br J Cancer 110(9):2224–2231. https://doi.org/10.1038/bjc.2014.164
Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR (2008) Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 105(30):10360–10365. https://doi.org/10.1073/pnas.0805326105
Rauf SMA, Endou A, Takaba H, Miyamoto A (2013) Effect of Y220C mutation on p53 and its rescue mechanism: a computer chemistry approach. Protein J 32(1):68–74. https://doi.org/10.1007/s10930-012-9458-x
Liu X, Wilcken R, Joerger AC, Chuckowree IS, Amin J, Spencer J, Fersht AR (2013) Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res 41(12):6034–6044. https://doi.org/10.1093/nar/gkt305
Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10(12):1321–1328. https://doi.org/10.1038/nm1146
Burmakin M, Shi Y, Hedstrom E, Kogner P, Selivanova G (2013) Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin Cancer Res 19(18):5092–5103. https://doi.org/10.1158/1078-0432.ccr-12-2211
Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A, Gluch A, Kel A, Sangfelt O, Selivanova G (2009) Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 15(5):441–453. https://doi.org/10.1016/j.ccr.2009.03.021
Roh JL, Ko JH, Moon SJ, Ryu CH, Choi JY, Koch WM (2012) The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer. Cancer Lett 325(1):35–41. https://doi.org/10.1016/j.canlet.2012.05.020
Zhao CY, Grinkevich V, Nikulenkov F, Bao W, Selivanova G (2010) Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle 9(9):1847–1855. https://doi.org/10.4161/cc.9.9.11545
Zhu H, Abulimiti M, Liu H, Su XJ, Liu CH, Pei HP (2015) RITA enhances irradiation-induced apoptosis in p53-defective cervical cancer cells via upregulation of IRE1alpha/XBP1 signaling. Oncol Rep 34(3):1279–1288. https://doi.org/10.3892/or.2015.4083
Friedler A, DeDecker BS, Freund SM, Blair C, Rudiger S, Fersht AR (2004) Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for “mutant conformation”. J Mol Biol 336(1):187–196
Demma M, Maxwell E, Ramos R, Liang L, Li C, Hesk D, Rossman R, Mallams A, Doll R, Liu M, Seidel-Dugan C, Bishop WR, Dasmahapatra B (2010) SCH529074, a small molecule activator of mutant p53, which binds p53 DNA Binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J Biol Chem 285(14):10198–10212. https://doi.org/10.1074/jbc.M109.083469
Margalit O, Simon AJ, Yakubov E, Puca R, Yosepovich A, Avivi C, Jacob-Hirsch J, Gelernter I, Harmelin A, Barshack I, Rechavi G, D’Orazi G, Givol D, Amariglio N (2012) Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function. Int J Cancer 131(4):E562–E568. https://doi.org/10.1002/ijc.26441
Pintus SS, Ivanisenko NV, Demenkov PS, Ivanisenko TV, Ramachandran S, Kolchanov NA, Ivanisenko VA (2013) The substitutions G245C and G245D in the Zn(2+)-binding pocket of the p53 protein result in differences of conformational flexibility of the DNA-binding domain. J Biomol Struct Dyn 31(1):78–86. https://doi.org/10.1080/07391102.2012.691364
Puca R, Nardinocchi L, Porru M, Simon AJ, Rechavi G, Leonetti C, Givol D, D’Orazi G (2011) Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle 10(10):1679–1689. https://doi.org/10.4161/cc.10.10.15642
Yu X, Vazquez A, Levine AJ, Carpizo DR (2012) Allele-specific p53 mutant reactivation. Cancer Cell 21(5):614–625. https://doi.org/10.1016/j.ccr.2012.03.042
Yu X, Blanden AR, Narayanan S, Jayakumar L, Lubin D, Augeri D, Kimball SD, Loh SN, Carpizo DR (2014) Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism. Oncotarget 5(19):8879
Blanden AR, Yu X, Wolfe AJ, Gilleran JA, Augeri DJ, O’Dell RS, Olson EC, Kimball SD, Emge TJ, Movileanu L, Carpizo DR, Loh SN (2015) Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore. Mol Pharmacol 87(5):825–831. https://doi.org/10.1124/mol.114.097550
Garufi A, Trisciuoglio D, Porru M, Leonetti C, Stoppacciaro A, D’Orazi V, Avantaggiati M, Crispini A, Pucci D, D’Orazi G (2013) A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells. J Exp Clin Cancer Res CR 32:72. https://doi.org/10.1186/1756-9966-32-72
Garufi A, Pucci D, D’Orazi V, Cirone M, Bossi G, Avantaggiati ML, D’Orazi G (2014) Degradation of mutant p53H175 protein by Zn(II) through autophagy. Cell Death Dis 5:e1271. https://doi.org/10.1038/cddis.2014.217
Garufi A, D’Orazi V, Crispini A, D’Orazi G (2015) Zn(II)-curc targets p53 in thyroid cancer cells. Int J Oncol 47(4):1241–1248. https://doi.org/10.3892/ijo.2015.3125
Lee KW, Bode AM, Dong Z (2011) Molecular targets of phytochemicals for cancer prevention. Nat Rev Cancer 11(3):211–218. http://www.nature.com/nrc/journal/v11/n3/suppinfo/nrc3017_S1.html
Singh S, Sharma B, Kanwar SS, Kumar A (2016) Lead phytochemicals for anticancer drug development. Front Plant Sci 7:1667. https://doi.org/10.3389/fpls.2016.01667
Wang H, Khor TO, Shu L, Su Z, Fuentes F, Lee J-H, Kong A-NT (2012) Plants against cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. Anti Cancer Agents Med Chem 12(10):1281–1305
Aggarwal M, Saxena R, Sinclair E, Fu Y, Jacobs A, Dyba M, Wang X, Cruz I, Berry D, Kallakury B, Mueller SC, Agostino SD, Blandino G, Avantaggiati ML, Chung FL (2016) Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth. Cell Death Differ. https://doi.org/10.1038/cdd.2016.48
Basak D, Punganuru SR, Srivenugopal KS (2016) Piperlongumine exerts cytotoxic effects against cancer cells with mutant p53 proteins at least in part by restoring the biological functions of the tumor suppressor. Int J Oncol 48(4):1426–1436. https://doi.org/10.3892/ijo.2016.3372
Mori A, Lehmann S, Kelly J, Kumagai T, Desmond JC, Pervan M, McBride WH, Kizaki M, Koeffler HP (2006) Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells. Can Res 66(6):3222
Wang X, Di Pasqua AJ, Govind S, McCracken E, Hong C, Mi L, Mao Y, Wu JY, Tomita Y, Woodrick JC, Fine RL, Chung FL (2011) Selective depletion of mutant p53 by cancer chemopreventive isothiocyanates and their structure-activity relationships. J Med Chem 54(3):809–816. https://doi.org/10.1021/jm101199t
A study of the effects of PEITC on oral cells with mutant p53. https://ClinicalTrials.gov/show/NCT01790204
Clark R, Lee S-H (2016) Anticancer properties of capsaicin against human cancer. Anticancer Res 36(3):837–843
Kuo YC, Kuo PL, Hsu YL, Cho CY, Lin CC (2006) Ellipticine induces apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. Life Sci 78(22):2550–2557. https://doi.org/10.1016/j.lfs.2005.10.041
Peng Y, Li C, Chen L, Sebti S, Chen J (2003) Rescue of mutant p53 transcription function by ellipticine. Oncogene 22(29):4478–4487. https://doi.org/10.1038/sj.onc.1206777
Kuo P-L, Hsu Y-L, Chang C-H, Lin C-C (2005) The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett 223(2):293–301
Wang F, Liu J, Robbins D, Morris K, Sit A, Liu Y-Y, Zhao Y (2011) Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells. Apoptosis 16(3):301–310. https://doi.org/10.1007/s10495-010-0559-8
Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, Stern AM, Mandinova A, Schreiber SL, Lee SW (2011) Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475(7355):231–234. https://doi.org/10.1038/nature10167
Punganuru SR, Madala HR, Venugopal SN, Samala R, Mikelis C, Srivenugopal KS (2016) Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties. Eur J Med Chem 107:233–244. https://doi.org/10.1016/j.ejmech.2015.10.052
Issaeva N, Friedler A, Bozko P, Wiman KG, Fersht AR, Selivanova G (2003) Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci USA 100(23):13303–13307. https://doi.org/10.1073/pnas.1835733100
Tal P, Eizenberger S, Cohen E, Goldfinger N, Pietrokovski S, Oren M, Rotter V (2016) Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides. Oncotarget 7(11):11817–11837. https://doi.org/10.18632/oncotarget.7857
Guida E, Bisso A, Fenollar-Ferrer C, Napoli M, Anselmi C, Girardini JE, Carloni P, Del Sal G (2008) Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells. Cancer Res 68(16):6550–6558. https://doi.org/10.1158/0008-5472.can-08-0137
Prabhu V, Hong B, Allen J, Zhang S, Lulla A, Dicker D, El-Deiry W (2016) Small molecule prodigiosin restores p53 tumor suppressor activity in chemoresistant colorectal cancer stem cells via c-Jun-mediated ΔNp73 inhibition and p73 activation. Cancer Res 76(7):1989–1999. https://doi.org/10.1158/0008-5472.CAN-14-2430
Darshan N, Manonmani HK (2015) Prodigiosin and its potential applications. J Food Sci Technol 52(9):5393–5407. https://doi.org/10.1007/s13197-015-1740-4
Hong B, Prabhu VV, Zhang S, van den Heuvel AP, Dicker DT, Kopelovich L, El-Deiry WS (2014) Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53. Cancer Res 74(4):1153–1165. https://doi.org/10.1158/0008-5472.can-13-0955
Tiwary R, Yu W, Sanders BG, Kline K (2011) alpha-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73. Breast Cancer Res BCR 13(1):R1. https://doi.org/10.1186/bcr2801
Acknowledgements
We acknowledge Department of Science and Technology-Science and Engineering Research Board (DST-SERB), Government of India for extramural Research Grant (EMR/2015/000761) to H. C. and Central University of Punjab, Bathinda, India for additional support.
Funding
This study was funded by the Department of Science and Technology-Science and Engineering Research Board, (DST-SERB), Government of India (EMR/2015/000761).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Author AB declares that he has no conflict of interest. Author SM declares that he has no conflict of interest. Author PS declares that he has no conflict of interest. Author SD declares that he has no conflict of interest. Author HC declares that he has no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Binayke, A., Mishra, S., Suman, P. et al. Awakening the “guardian of genome”: reactivation of mutant p53. Cancer Chemother Pharmacol 83, 1–15 (2019). https://doi.org/10.1007/s00280-018-3701-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-018-3701-x